Agenda
Applications for consideration at this meeting
- 1376.1 70 gene signature (MammaPrint) for use in breast cancer to quantify the risk of disease recurrence and predict adjuvant chemotherapy benefit
- 1408 A prognostic RT-qPCR test run locally for ER+ve /HER2-ve breast cancer that determines the risk of early and late metastasis in node negative and positive cancer under endocrine treatment.
- 1473 A 50 gene signature assay for predicting breast cancer recurrence
- 1546.1 Abdominoplasty with repair of rectus diastasis (also known as rectus divarication) following pregnancy
- 1564 Review of immunoglobulin use for Chronic Inflammatory Demyelinating Polyneuropathy
- 1578 Arthroscopic injection of a bioadhesive hydrogel implant (JointRep™), in conjunction with microfracture, for treatment of osteochondral defects of the knee
- 1585 Genetic testing for the diagnosis of early-onset or familial neuromuscular disorders
- 1628 Alpha-1-Antitrypsin Genotyping
- 1631 Home sleep apnoea test utilizing peripheral arterial tone
- 1632 PSMA PET/CT imaging for informing treatment of patients with prostate cancer
- 1635 Transcatheter aortic valve implantation via transfemoral delivery using the balloon-expandable valve system for patients at low risk for surgery
- 1640 Transcatheter Aortic Valve Implantation (TAVI) via transfemoral delivery for patients at low risk for surgery
- 1647 Brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma
- 1651 Integrated, closed-system, extracorporeal photopheresis systems for the treatment of chronic graft-versus-host disease
- 1663 Review of Continuous Glucose Monitoring (CGM) products provided through the CGM Initiative
- 1676 Amendments to eligibility criteria for tisagenlecleucel for treatment of relapsed or refractory diffuse large B-cell lymphoma – amend clinical criteria for patients with Transformed Follicular Lymphoma (TFL) and propose inclusion of patients with grade 3B follicular lymphoma (3B FL)
We considered applications 1376.1, 1408 and 1473 together as one agenda item (Gene Expression Profiling Tests).
Related information
Committee: